Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease - A Population-based Cohort Study

被引:7
|
作者
Ebrahimi, Fahim [1 ,2 ,11 ]
Simon, Tracey G. [1 ,3 ,4 ,5 ]
Hagstrom, Hannes [6 ,7 ]
Soderling, Jonas [1 ,8 ]
Wester, Axel [7 ]
Roelstraete, Bjorn [1 ]
Ludvigsson, Jonas F. [1 ,9 ,10 ]
机构
[1] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[2] Univ Ctr Gastrointestinal & Liver Dis, Dept Gastroenterol & Hepatol, Basel, Switzerland
[3] Massachusetts Gen Hosp, Div Gastroenterol & Hepatol, Boston, MA 02114 USA
[4] Harvard Med Sch, Boston, MA USA
[5] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit CTEU, Boston, MA USA
[6] Karolinska Univ Hosp, Dept Upper GI, Div Hepatol, Stockholm, Sweden
[7] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden
[8] Karolinska Inst, Dept Med Solna, Clin Epidemiol Unit, Stockholm, Sweden
[9] Orebro Univ Hosp, Dept Pediat, Orebro, Sweden
[10] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA
[11] Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden
基金
瑞士国家科学基金会;
关键词
Hospitalization; Immune System; Infection; Metabolic Syndrome; Nonalcoholic Fatty Liver Disease; FIBROSIS STAGE; BACTERIAL-INFECTIONS; EPIDEMIOLOGY; ASSOCIATION; MECHANISMS; MORTALITY; CIRRHOSIS; OUTCOMES; NASH;
D O I
10.1016/j.cgh.2023.05.013
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: It has been suggested that patients with nonalcoholic fatty liver disease (NAFLD) might be at increased risk of severe infections, but large-scale data from cohorts with biopsy-proven NAFLD are lacking.METHODS: Population-based cohort study including all Swedish adults with histologically confirmed NAFLD (n = 12,133) from 1969 to 2017. NAFLD was defined as simple steatosis (n = 8232), nonfibrotic steatohepatitis (n = 1378), noncirrhotic fibrosis (n = 1845), and cirrhosis (n = 678). Patients were matched to 5 pound population comparators (n = 57,516) by age, sex, calendar year, and county. Swedish national registers were used to ascertain incident severe infections requiring hospital admission. Multivariable adjusted Cox regression was used to estimate hazard ratios in NAFLD and histopathological subgroups.RESULTS: Over a median of 14.1 years, 4517 (37.2%) patients with NAFLD vs 15,075 (26.2%) comparators were hospitalized for severe infections. Patients with NAFLD had higher incidence of severe infections than comparators (32.3 vs. 17.0/1000 person-years; adjusted hazard ratio [aHR], 1.71; 95% confidence interval, 1.63L1.79). The most frequent infections were respiratory (13.8/1000 person-years) and urinary tract infections (11.4/1000 person-years). The absolute risk difference at 20 years after NAFLD diagnosis was 17.3%, equal to one extra severe infection in every 6 patients with NAFLD. Risk of infection increased with worsening histological severity of NAFLD (simple steatosis [aHR, 1.64], nonfibrotic steatohepatitis [aHR, 1.84], noncirrhotic fibrosis [aHR, 1.77], and cirrhosis [aHR, 2.32]. Also compared with their full siblings, patients with NAFLD were at increased risk of severe infections (aHR, 1.54; 95% confidence interval, 1.40-1.70).CONCLUSIONS: Patients with biopsy-proven NAFLD were at significantly higher risk of incident severe infection requiring hospitalization both compared with the general population and compared with siblings. Excess risk was evident across all stages of NAFLD and increased with worsening disease severity.
引用
收藏
页码:3346 / 3355.e19
页数:29
相关论文
共 50 条
  • [1] Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study
    Fujii, Hideki
    Iwaki, Michihiro
    Hayashi, Hideki
    Toyoda, Hidenori
    Oeda, Satoshi
    Hyogo, Hideyuki
    Kawanaka, Miwa
    Morishita, Asahiro
    Munekage, Kensuke
    Kawata, Kazuhito
    Yamamura, Sakura
    Sawada, Koji
    Maeshiro, Tatsuji
    Tobita, Hiroshi
    Yoshida, Yuichi
    Naito, Masafumi
    Araki, Asuka
    Arakaki, Shingo
    Kawaguchi, Takumi
    Noritake, Hidenao
    Ono, Masafumi
    Masaki, Tsutomu
    Yasuda, Satoshi
    Tomita, Eiichi
    Yoneda, Masato
    Kawada, Norifumi
    Tokushige, Akihiro
    Kamada, Yoshihiro
    Takahashi, Hirokazu
    Ueda, Shinichiro
    Aishima, Shinichi
    Sumida, Yoshio
    Nakajima, Atsushi
    Okanoue, Takeshi
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (02) : 370 - 379
  • [2] Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
    Simon, Tracey G.
    Roelstraete, Bjorn
    Sharma, Rajani
    Khalili, Hamed
    Hagstrom, Hannes
    Ludvigsson, Jonas F.
    [J]. HEPATOLOGY, 2021, 74 (05) : 2410 - 2423
  • [3] Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease
    Alsaif, Faisal A.
    Alqahtani, Sara H.
    Alsadoon, Amani M.
    Alswat, Khalid A.
    Abdo, Ayman A.
    Hassanain, Mazen M.
    Alsharabi, Abdulsalam B.
    Aljuhani, Ghadeer R.
    Alkhalidi, Hisham M.
    Elsharkawy, Mohammad S.
    Alotaibi, Maram A.
    Sanai, Faisal M.
    Al-hamoudi, Waleed K.
    [J]. SAUDI JOURNAL OF GASTROENTEROLOGY, 2020, 26 (04): : 204 - 209
  • [4] Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease
    Senates, Ebubekir
    Yilmaz, Yusuf
    Colak, Yasar
    Ozturk, Oguzhan
    Altunoz, Mustafa Erhan
    Kurt, Ramazan
    Ozkara, Selvinaz
    Aksaray, Sebahat
    Tuncer, Ilyas
    Ovunc, Ayse Oya Kurdas
    [J]. METABOLIC SYNDROME AND RELATED DISORDERS, 2011, 9 (04) : 287 - 290
  • [5] THE PREVALENCE AND ASSOCIATION OF HYPOTHYROIDISM IN PATIENTS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE OR NONALCOHOLIC STEATOHEPATITIS
    Long, Michelle
    Rutherford, Anna E.
    Chung, Raymond I.
    Corey, Kathleen E.
    [J]. HEPATOLOGY, 2010, 52 (04) : 657A - 657A
  • [6] Risk of Cancer in Biopsy-Proven Alcohol-Related Liver Disease: A Population-Based Cohort Study of 3410 Persons
    Hagstrom, Hannes
    Thiele, Maja
    Sharma, Rajani
    Simon, Tracey G.
    Roelstraete, Bjorn
    Soderling, Jonas
    Ludvigsson, Jonas F.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (04) : 918 - +
  • [7] Nonalcoholic Fatty Liver Disease and Risk of Dementia A Population-Based Cohort Study
    Shang, Ying
    Widman, Linnea
    Hagstrom, Hannes
    [J]. NEUROLOGY, 2022, 99 (06) : E574 - E582
  • [8] Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients
    Hagstrom, Hannes
    Thiele, Maja
    Roelstraete, Bjorn
    Soderling, Jonas
    Ludvigsson, Jonas F.
    [J]. GUT, 2021, 70 (01) : 170 - 179
  • [9] Quantitative Diagnosis of Nonalcoholic Fatty Liver Disease with Ultrasound Attenuation Imaging in a Biopsy-Proven Cohort
    Huang, Yun-Lin
    Bian, Hua
    Zhu, Yu-Li
    Yan, Hong-Mei
    Wang, Wen-Ping
    Xia, Ming-Feng
    Dong, Yi
    Gao, Xin
    [J]. ACADEMIC RADIOLOGY, 2023, 30 : S155 - S163
  • [10] Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease
    Arai, Taeang
    Atsukawa, Masanori
    Tsubota, Akihito
    Kawano, Tadamichi
    Koeda, Mai
    Yoshida, Yuji
    Tanabe, Tomohide
    Okubo, Tomomi
    Hayama, Korenobu
    Iwashita, Ai
    Itokawa, Norio
    Kondo, Chisa
    Kaneko, Keiko
    Kawamoto, Chiaki
    Hatori, Tsutomu
    Emoto, Naoya
    Iio, Etsuko
    Tanake, Yasuhito
    Iwakiri, Katsuhiko
    [J]. PLOS ONE, 2019, 14 (11):